全文获取类型
收费全文 | 121671篇 |
免费 | 10899篇 |
国内免费 | 306篇 |
学科分类
医药卫生 | 132876篇 |
出版年
2023年 | 759篇 |
2022年 | 510篇 |
2021年 | 2915篇 |
2020年 | 1734篇 |
2019年 | 2856篇 |
2018年 | 3275篇 |
2017年 | 2349篇 |
2016年 | 2572篇 |
2015年 | 2915篇 |
2014年 | 4195篇 |
2013年 | 5546篇 |
2012年 | 8476篇 |
2011年 | 8787篇 |
2010年 | 4824篇 |
2009年 | 4267篇 |
2008年 | 7190篇 |
2007年 | 7464篇 |
2006年 | 7013篇 |
2005年 | 6926篇 |
2004年 | 6350篇 |
2003年 | 5929篇 |
2002年 | 5572篇 |
2001年 | 2145篇 |
2000年 | 1983篇 |
1999年 | 1931篇 |
1998年 | 1384篇 |
1997年 | 1078篇 |
1996年 | 762篇 |
1995年 | 875篇 |
1994年 | 825篇 |
1993年 | 782篇 |
1992年 | 1347篇 |
1991年 | 1241篇 |
1990年 | 1203篇 |
1989年 | 1100篇 |
1988年 | 1014篇 |
1987年 | 1020篇 |
1986年 | 993篇 |
1985年 | 1029篇 |
1984年 | 877篇 |
1983年 | 742篇 |
1982年 | 656篇 |
1981年 | 567篇 |
1980年 | 518篇 |
1979年 | 667篇 |
1978年 | 551篇 |
1977年 | 455篇 |
1976年 | 434篇 |
1974年 | 424篇 |
1972年 | 375篇 |
排序方式: 共有10000条查询结果,搜索用时 406 毫秒
1.
2.
3.
4.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
5.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
6.
7.
Rupa Narayan MD Traci M. Blonquist MS Ashkan Emadi MD PhD Robert P. Hasserjian MD Meghan Burke BS Christopher Lescinskas BS Donna S. Neuberg ScD Andrew M. Brunner MD Gabriela Hobbs MD Hanno Hock MD PhD Steven L. McAfee MD Yi-Bin Chen MD Eyal Attar MD Timothy A. Graubert MD Christina Bertoli MSN Jenna A. Moran MSN Meghan K. Bergeron MSN Julia E. Foster MSN Aura Y. Ramos BSN Tina T. Som BSN Megan K. Vartanian BSN RN Jennifer L. Story LPN Kristin McGregor MS Molly Macrae BS Tanya Behnan BS Margaret C. Wey PhD Jessica Rae BSN Frederic I. Preffer PhD Patricia Lesho BA Vu H. Duong MD Mason L. Mann BA Karen K. Ballen MD Christine Connolly BS Philip C. Amrein MD Amir T. Fathi MD 《Cancer》2020,126(6):1264-1273
8.
Liam Masterson James Howard Jazmina Gonzalez-Cruz Christopher Jackson Catherine Barnett Lewis Overton Howard Liu Rahul Ladwa Fiona Simpson Margie McGrath Ben Wallwork Terry Jones Christian Ottensmeier Melvin L.K. Chua Chris Perry Rajiv Khanna Benedict Panizza Sandro Porceddu Matt Lechner 《International journal of cancer. Journal international du cancer》2020,146(8):2305-2314
Now is an exciting era of development in immunotherapy checkpoint inhibitors and their effect on the treatment of NPC. While the general prognosis of R/M disease is poor, immunotherapy offers some promise in a malignancy associated with EBV and characterized by a peritumoural immune infiltrate. Our study aims to review past and on-going clinical trials of monoclonal antibody therapies against the checkpoint inhibitors (e.g. PD1 and CTLA-4), in R/M NPC. All randomized and nonrandomized controlled trials involving immune checkpoint inhibitor interventions for treatment of NPC were included in the study. We utilized a validated “risk of bias” tool to assess study quality. Four separate Phase I–II trials report the potential of PD1 inhibitor treatment for patients with NPC. Within the observed groups, camrelizumab combined with chemotherapy achieved an objective response in 91% of patients as first-line treatment for metastatic NPC (PFS 68% at 1-year) but this was associated with a high rate of grade >3 adverse events (87%; CTCAE version 4.03). The remaining three studies focused on recurrent NPC disease in patients who had received at least one line of prior chemotherapy. Within this group, camrelizumab monotherapy achieved an objective response in 34% of patients (PFS 27% at 1-year; range across all three studies 20.5–34%). No NPC trial has yet reported on specific outcomes for non-PD1 checkpoint inhibitors but 11 on-going studies include alternative targets (e.g. PD-L1/CTLA-4) as combination or monotherapy treatments. In considering checkpoint immunotherapies for NPC, initial results show promise for anti-PD1 interventions. Further phase I–III trials are in progress to clarify clinical outcomes, fully determine safety profiles, and optimize drug combinations and administration schedules. 相似文献
9.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
10.